Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Brain-derived-neurotrophic-factor accelerant polypeptide and application

A neurotrophic factor and enhancer technology, applied in nervous system diseases, peptides, depsipeptides, etc., can solve the problems of large molecular weight and reduce drug efficacy, so as to improve the intake of sugar water, improve depression symptoms, and reduce foraging latency. Effect

Inactive Publication Date: 2017-02-01
SUZHOU PULUODA BIOLOGICAL SCI & TECH
View PDF2 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, BDNF itself has a large molecular weight and is antigenic. Long-term use in the human body will produce a neutralization reaction and reduce the efficacy of the drug.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Brain-derived-neurotrophic-factor accelerant polypeptide and application
  • Brain-derived-neurotrophic-factor accelerant polypeptide and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Effect of brain-derived neurotrophic factor promoter polypeptide on BDNF content in brain tissue of chronic unpredictable stress model rats.

[0016] SD rats were used as test animals, and 60 rats, half male and half male, with a body weight of 180-220 g, were randomly divided into 6 groups, high-dose group, middle-dose group, low-dose group, positive control group, model group, Blank group, each group l0. Establish a rat chronic unpredictable stress model: the stress content is: restraint for 4 hours; wet bedding overnight; shaking for 1 hour (160r / min); fasting for 12 hours; Clamp the tail for 1 min; crowd overnight (8 / cage). Two stresses were used during the day, and one stress was used at night, and the stress was continued for 4 weeks. Administer after the last stimulation. Dosing regimen: the treatment group was subcutaneously injected with the polypeptide of the present invention at doses of 30, 15, and 7.5 mg / Kg, the control group was given fluoxetine at a do...

Embodiment 2

[0022] Effects of brain-derived neurotrophic factor-promoter peptides in a mouse forced-swim stress-despair model.

[0023] Using ICR mice as the test animals, 50 mice, half male and half male, weighing 18-22g, were randomly divided into 5 groups: high-dose group, middle-dose group, low-dose group, positive control group, blank group, Each group l0. The treatment group was subcutaneously injected with the polypeptide of the present invention at doses of 30, 15, and 7.5 mg / Kg, the control group was given fluoxetine at a dose of 10 mg / Kg, and the blank group was given normal saline for 7 consecutive days. One hour after administration on the seventh day, the mice were subjected to a forced swimming test. The mice were forced to swim in water at 20-25°C for 6 minutes, and the immobility time within 4 minutes after recording was recorded. The time spent floating with the head out of the water is used to evaluate the effect of the polypeptide of the present invention on the model ...

Embodiment 3

[0029] Effects of brain-derived neurotrophic factor-promoter peptides in a mouse tail-suspension stress hopelessness model.

[0030] Using ICR mice as the test animals, 50 mice, half male and half male, weighing 18-22g, were randomly divided into 5 groups: high-dose group, middle-dose group, low-dose group, positive control group, blank group, Each group l0. The treatment group was subcutaneously injected with the polypeptide of the present invention at doses of 30, 15, and 7.5 mg / Kg, the control group was given fluoxetine at a dose of 10 mg / Kg, and the blank group was given normal saline for 7 consecutive days. 1h after administration on the 7th day, the mice were subjected to a tail-suspension test, and the mice were fixed with adhesive tape at a place about 1 cm from the end of their tails, and the mice were kept in a suspended state for 6 minutes, and the immobility time of 4 minutes after recording was used to evaluate this product. Effects of Invention Peptides on a Mou...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicine, in particular to a polypeptide capable of simulating the brain-derived-neurotrophic-factor physiological function and reducing depressive symptoms. The sequence is SEQ ID NO:1, and the SEQ ID NO:1 is a bran-new sequence. The polypeptide has the advantages that the BDNF content of chronic inscrutable stress model rat brain tissue can be increased. The in-vivo pharmacological result shows that depressive symptoms of acute and chronic depression model animals can be improved through the polypeptide, and the polypeptide can serve as an effective candidate treating method for clinical depression.

Description

technical field [0001] The invention relates to a brain-derived neurotrophic factor promoter polypeptide and its application, in particular to a polypeptide that can simulate the physiological function of the brain-derived neurotrophic factor and relieve depression symptoms. Background technique [0002] Depression (Depression) is a mental disease characterized by significant and persistent low mood, slow thinking, cognitive function impairment, decreased willpower and physical symptoms, which has a high recurrence rate, high disability rate and high characteristics of suicide risk. According to WHO statistics, there are 350 million depression patients in the world. By 2020, the disease burden brought by depression to human beings will be second only to ischemic heart disease, and become the second largest cause of human disability and death. [0003] Over the past decade, a wealth of clinical and basic research has led researchers to a deeper understanding of depression, a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/00A61K38/16A61P25/24
CPCA61K38/00C07K14/001
Inventor 罗瑞雪
Owner SUZHOU PULUODA BIOLOGICAL SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com